GlassScriptPhysician profile
Sara B Canchola
NPI 1215230446
$3,280.28
in general payments reported to CMS, 2019-2025
28 companies · $475 in 2025
The $475 reported for 2025 was more than what 82% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $505 · 2022: $1,092 · 2023: $734 · 2024: $474 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.06 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $514.00 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $323.75 | 2021-2025 | |
| Exeltis, USA INC. | $301.93 | 2022-2025 | Slynd |
| Sumitomo Pharma America, INC. | $248.47 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $235.87 | 2022-2025 | Veozah |
| Therapeuticsmd, INC. | $222.39 | 2021-2022 | |
| Organon LLC | $147.44 | 2021-2025 | Nexplanon, Jada System |
| Aspira Women'S Health INC | $146.85 | 2021-2022 | |
| Myovant Sciences INC. | $127.53 | 2021-2022 | |
| Hologic Sales and Service, LLC | $86.41 | 2022-2023 | Aptima |
| Pfizer INC. | $86.39 | 2023-2024 | |
| Agile Therapeutics, INC. | $85.59 | 2022-2023 | Twirla |
| Avion Pharmaceuticals | $74.91 | 2021-2022 | |
| Biogen, INC. | $73.69 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $72.42 | 2023-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $70.35 | 2021-2023 | |
| Scynexis, INC. | $65.57 | 2022 | |
| Evofem Biosciences, INC. | $64.21 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $62.99 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $60.31 | 2023-2025 | Gardasil 9, Gardasil |
| Millicent US INC | $43.65 | 2025 | Intrarosa, Femlyv |
| Novo Nordisk INC | $40.93 | 2023-2025 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $31.52 | 2022 | |
| Amgen INC. | $29.66 | 2022-2024 | Evenity, Prolia |
| Almatica Pharma LLC | $22.24 | 2024 | Loreev Xr |
| Smith+Nephew, INC. | $15.01 | 2025 | Pico 14, Pico 7 |
| Ascend Therapeutics US, LLC | $13.12 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Canchola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.